文献速递认知障碍与痴呆

轻度认知障碍随机对照试验中安慰剂组表现的变异性来源

Randomized controlled trials in mild cognitive impairment: Sources of variability.
PubMed 文献 · Neurology · 2017-04-05

该研究比较了7项轻度认知障碍(MCI)随机对照试验中安慰剂组的数据,包括2项美国国家老龄化研究所(NIA)支持的试验(ADCS MCI试验和ADNI模拟临床试验)以及涉及利斯的明、加兰他敏、罗非昔布和多奈哌齐的产业界申办试验。结果显示,不同试验中安慰剂组向临床终点进展的情况差异很大:NIA支持的试验中安慰剂组表现普遍随时间恶化,而产业界试验中安慰剂组大多稳定或改善。APOE4携带状态对结局的影响符合预期。

要点

  • 不同MCI试验中安慰剂组向临床终点进展的速率差异很大
  • NIA支持的试验中安慰剂组认知表现普遍随时间恶化
  • 产业界申办的试验中安慰剂组大多表现稳定或改善

核心结论

  • 尽管7项研究采用了看似相似的MCI诊断标准,但标准实施差异很大,导致安慰剂组表现变异性显著。

研究设计与样本

  • 研究分析了2项NIA支持的MCI随机对照试验(ADCS MCI试验和ADNI模拟临床试验)以及4种药物(利斯的明、加兰他敏、罗非昔布、多奈哌齐)的产业界申办试验的安慰剂组数据。

主要发现

  • 不同试验中安慰剂组向预设临床终点进展的情况差异很大。
  • NIA支持的试验(ADCS和ADNI)中安慰剂组表现普遍随时间恶化。
  • 产业界申办的试验中安慰剂组大多表现稳定或改善。
  • APOE4携带状态对研究结局(包括进展率和认知子量表)的影响符合预期。

临床怎么用

  • 解读MCI随机对照试验结果时需考虑安慰剂组表现的异质性,尤其是产业界试验与学术试验之间的差异。

局限性

  • 研究仅纳入7项试验,样本来源有限;部分试验的APOE数据可能不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the variability in performance among placebo groups in randomized controlled trials for mild cognitive impairment (MCI). METHODS: Placebo group data were obtained from 2 National Institute on Aging (NIA) MCI randomized controlled trials, the Alzheimer's Disease Cooperative Study (ADCS) MCI trial and the Alzheimer's Disease Neuroimaging Initiative (ADNI), which is a simulated clinical trial, in addition to industry-sponsored clinical trials involving rivastigmine, galantamine, rofecoxib, and donepezil. The data were collated for common measurement instruments. The performance of the placebo participants from these studies was tracked on the Alzheimer's Disease Assessment Scale-cognitive subscale, Mini-Mental State Examination, and Clinical Dementia Rating-sum of boxes, and for progression on these measures to prespecified clinical study endpoints. APOE status, where available, was also analyzed for its effects. RESULTS: The progression to clinical endpoints varied a great deal among the trials. The expected performances were seen for the participants in the 2 NIA trials, ADCS and ADNI, with generally worsening of performance over time; however, the industry-sponsored trials largely showed stable or improved performance in their placebo participants. APOE4 carrier status influenced results in an expected fashion on the study outcomes, including rates of progression and cognitive subscales. CONCLUSIONS: In spite of apparently similar criteria for MCI being adopted by the 7 studies, the implementation of the criteria varied a great deal. Several explanations including instruments used to characterize participants and variability among study populations contributed to the findings.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Petersen RC, Thomas RG, Aisen PS, et al. Randomized controlled trials in mild cognitive impairment: Sources of variability. Neurology. 2017. PMID: 28381516. doi:10.1212/WNL.0000000000003907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。